Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acacia dealbata pollen is an allergenic extract derived from the pollen of the silver wattle tree (Acacia dealbata). It is a biological product used for the diagnosis and treatment of patients with immediate hypersensitivity (Type I) allergies to Acacia pollen. For diagnostic purposes, the extract is used in percutaneous (scratch/prick) or intradermal skin testing to identify specific IgE-mediated sensitivity. For therapeutic use, it is administered via subcutaneous immunotherapy (allergy shots) to desensitize the patient's immune system, typically by shifting the immune response from a Th2-dominated allergic profile to a Th1-dominated or regulatory T-cell profile, often accompanied by the production of blocking IgG4 antibodies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Acacia dealbata pollen.